WuXi Biologics, a global open-access biologics technology platform company, plans to invest S$80 million (US$60 million) and hire approximately 150 employees to establish a biologics manufacturing facility in Singapore. It would be the company’s 10th global drug substance manufacturing facility.
A total of approximately 4,500 L bioreactor capacity will be installed, including two 2,000 L traditional fed-batch and one 500 L perfusion-based continuous processing units.
The manufacturing facility, supported by the Singapore Economic Development Board (EDB), will be capable of handling both clinical and small volume commercial production. An early-stage bioprocess development lab also will be included.
“We are delighted that WuXi Biologics has chosen Singapore as its first overseas manufacturing site in Asia,” Dr. Beh Swan Gin, chairman of Singapore’s EDB, said. “This will introduce the company’s next-generation bioprocessing technology platform to this region. WuXi Biologics’ decision is a testament to Singapore’s strong talent pool for the biomedical sciences sector and our capabilities in advanced manufacturing. Its presence here will also strengthen our ecosystem for supporting biotech companies from Singapore and beyond.”
Headquartered in Wuxi city, Jiangsu province, China, WuXi Biologics provides biologics solutions with a mission to accelerate discovery, development, and manufacturing.
(Source: WuXi Biologics)
